您当前的位置: 首页 > 资源详情

CIDRAP,9月20日,Pfizer says COVID-19 vaccine safe, immune-producing in younger children

编译者:YUTING发布时间:Sep 25, 2021点击量:360 来源栏目:最新研究

Today Pfizer-BioNTech released results from the first phase 2/3 trial of its COVID-19 mRNA vaccine on children ages 5 to 11, and said the vaccine was both safe and produced neutralizing antibodies to the novel coronavirus.

The trail considered a two-dose regimen of 10 micrograms (µg) administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older, Pfizer said in a press release. The study included 2,268 participants. The trial is also studying that dose in children ages 6 months to 11 years.

"Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," said Pfizer CEO Albert Bourla.

Pfizer said it would be submitting applications for use to regulatory bodies as soon as possible, and ideally would see vaccination begin in this age group by the beginning of winter.

Pediatric infection with COVID-19, though rarely serious, is on the rise in the United States as the age-group remains one of the last eligible to receive COVID-19 vaccine, schools have resumed in-person instruction, and the Delta (B1617.2) variant continues to spread in communities with low vaccination rates.

Currently, roughly one in five new COVID-19 cases are confirmed in children in the United States.

FDA likely to OK Pfizer booster this week

The Pfizer vaccine is currently the only vaccine approved by the Food and Drug Administration (FDA) for use in those 16 and older, and under emergency use authorization for those 12 through 15 years of age.

On Sep 17, a committee of advisers to the FDA unanimously said booster shots, or third doses of the vaccine, should be made available to Americans 65 and older and those at risk for severe disease from COVID-19.

The FDA is likely to authorize booster shots of the Pfizer COVID-19 vaccine this week for people ages 65 and older and those at high risk of getting severe COVID-19, the New York Times reports.

The likely outcome is different than the one touted by the Biden administration just last month, when it promised all Americans could be eligible for a booster dose of vaccine by today, Sep 20, if it had been at least 6 months from their second dose of vaccine.

In separate interviews on Fox News and CNN, National Institutes of Health Director Francis Collins, MD, and White House chief medical adviser Anthony Fauci, MD, said they expect to see broader approval of COVID-19 vaccine boosters in the coming weeks and months as the FDA and the Centers for Disease Control and Prevention (CDC) get more data on waning immunity.

Fauci told NBC's Meet the Press yesterday that data on booster shots for those who received the Moderna or Johnson & Johnson vaccines is a few weeks away from being reviewed by the FDA.

The CDC COVID Data Tracker shows 54.6% of Americans are fully vaccinated, and 63.8% have received at least one dose of COVID-19 vaccine.

Yesterday the United States reported 36,794 COVID-19 cases, and 291 deaths, according to the Johns Hopkins COVID-19 tracker.

The 7-day average of new daily cases is 147,355, with 2,012 daily deaths, according to the Washington Post tracker. COVID-19 deaths rose by 22% in the past week.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 Medicalxpress,1月17日,Additional antibodies may protect against COVID
  2. 2 Medicalxpress,1月14日,Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19
  3. 3 Medicalxpress,1月13日,WHO recommends two new drugs to treat patients with COVID-19
  4. 4 1月13日_研究发现阻断人类细胞BRD2的产生可防止SARS-CoV-2感染
  5. 5 1月13日_科学家识别出可预防COVID-19严重疾病的人体基因变异
  6. 6 Medicalxpress,1月13日,Preliminary research suggests SARS-CoV-2 virus less infectious within five minutes of exposure to air
  7. 7 Medicalxpress,1月13日,Maternal COVID-19 infection increases risks of preterm birth, low birth weight and stillbirth
  8. 8 Medicalxpress,1月12日,Researchers use artificial intelligence to guide the search for the next SARS-like virus
  9. 9 1月12日_研究人员发现可抑制SARS-CoV-2复制的化合物
  10. 10 1月12日_全球研究揭示儿童严重COVID-19相关风险因素

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190